Dianthus Therapeutics Inc. (DNTH) Annual Income Statement (USD)
DNTH Quarterly Financials (USD)
Frequently Asked Questions About Dianthus Therapeutics Inc. (DNTH) Stock
Dianthus Therapeutics Inc.'s (DNTH) last reported annual revenue was USD 2.83 Million.
Dianthus Therapeutics Inc.'s (DNTH) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A
Dianthus Therapeutics Inc.'s(DNTH) is not profitable as of its last reported annual financials.
The net profit margin for Dianthus Therapeutics Inc.'s(DNTH) from its laster reported year is -1541.22%
The return on equity (ROE) for Dianthus Therapeutics Inc.'s(DNTH) from its last reported annual financials is : N/A
The return on assets (ROA) for Dianthus Therapeutics Inc.'s(DNTH) from its last reported annual financials is : N/A
The return on invested capital (ROIC) for Dianthus Therapeutics Inc.'s(DNTH) from its last reported annual financials is : N/A
The Debt to Equity ratio for Dianthus Therapeutics Inc.'s(DNTH) from its last reported annual financials is : N/A
The dividend yield for Dianthus Therapeutics Inc.'s(DNTH) from its laster reported year is N/A
Dianthus Therapeutics Inc.'s(DNTH) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
There is nothing we particularly dislike
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DNTH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
